Key clinical point: The study was halted early because of short-lived response and disease hyperprogression.
Major finding: Median progression-free survival was 2.7 months, and median overall survival was 6.7 months
Study details: An interim analysis of a phase 2 trial with 12 patients with peripheral T-cell lymphomas.
Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Bennani reported research funding and advisory board activities for Bristol-Myers Squibb and others.
Bennani NN et al. ASCO 2019, Abstract 467.